GMED - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 24, 2026

5.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Cost of sales decreased due to a favorable year-over-year comparison of inventory step-up amortization, which was a one-time effect.. A jury awarded $28.7 million in damages against NuVasive in the Pimenta litigation, plus interest and costs, resulting in a $43.1 million liability recorded as of December 31, 2025.. Revenue increased 16.7% to $2.94B

Top Concerns

!A jury awarded $28.7 million in damages against NuVasive in the Pimenta litigation, plus interest and costs, resulting in a $43.1 million liability recorded as of December 31, 2025.
!Multiple patent infringement lawsuits are ongoing, with potential for significant monetary damages and injunctive relief, although current outcomes are uncertain.
!Cybersecurity and Data Privacy (medium)
!Integration and Merger-Related Costs (medium)

Top Positives

+Revenue growth was driven by the inclusion of Nevro sales and strong performance in Musculoskeletal Solutions, particularly in the US market.
+Operating expenses, especially SG&A, increased significantly due to Nevro integration costs and litigation provisions, negatively impacting margins.
+Operating cash flow generation improved significantly due to higher net income and favorable working capital movements.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

5.0/10

Management tone is cautiously measured.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

6.0/10

Overall risk profile shows cybersecurity and data privacy as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

7.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.